Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2528–2534. doi: 10.1128/aac.39.11.2528

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

D Henry 1, G E Ruoff 1, J Rhudy 1, A Puopolo 1, M Drehobl 1, J Schoenberger 1, G Giguere 1, J J Collins 1
PMCID: PMC162978  PMID: 8585739

Abstract

Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5- or 10-day treatment with cefuroxime axetil with those of 10-day treatment with amoxicillin-clavulanate in the treatment of secondary bacterial infections of acute bronchitis. Patients received either 5 or 10 days of treatment (n = 177 in each group) with cefuroxime axetil at 250 mg twice daily or 10 days of treatment (n = 183) with amoxicillin-clavulanate at 500 mg three times daily. Patients in the cefuroxime axetil (5 days) group received placebo on days 6 to 10. Bacteriologic assessments were based on sputum specimen cultures obtained preceding and, when possible, following treatment. Organisms were isolated from the pretreatment sputum specimens of 242 of 537 (45%) patients, with the primary pathogens being Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus (28, 25, 13, 9, and 8% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 87% (52 of 60), 91% (53 of 58), and 86% (60 of 70) of bacteriologically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. A satisfactory clinical outcome (cure or improvement) was achieved in 82% (107 of 130), 86% (117 of 136), and 83% (130 of 157) of the clinically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. Treatment with amoxicillin-clavulanate was associated with a significantly higher incidence of drug-related adverse events than was treatment with cefuroxime axetil for either 5 or 10 days (P = 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (37 versus 19 and 15%, respectively; P < 0.001), particularly diarrhea and nausea. These results indicate that treatment with cefuroxime axetil at 250 mg twice daily for 5 days is as effective as treatment for 10 days with either the same dose of cefuroxime axetil or amoxicillin-clavulanate at 500 mg three times daily in patients with acute bronchitis. In addition, treatment with cefuroxime axetil for either 5 or 10 days is associated with significantly fewer gastrointestinal adverse events, particularly diarrhea and nausea, than is 10-day treatment with amoxicillin-clavulanate.

Full Text

The Full Text of this article is available as a PDF (235.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arguedas A. G., Arrieta A. C., Stutman H. R., Akaniro J. C., Marks M. I. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. J Antimicrob Chemother. 1991 Mar;27(3):311–318. doi: 10.1093/jac/27.3.311. [DOI] [PubMed] [Google Scholar]
  2. Camacho A. E., Cobo R., Otte J., Spector S. L., Lerner C. J., Garrison N. A., Miniti A., Mydlow P. K., Giguere G. C., Collins J. J. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med. 1992 Sep;93(3):271–276. doi: 10.1016/0002-9343(92)90232-z. [DOI] [PubMed] [Google Scholar]
  3. Doern G. V. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis. Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):75–77. doi: 10.1016/0732-8893(91)90092-t. [DOI] [PubMed] [Google Scholar]
  4. Doern G. V., Tubert T. A. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):349–352. doi: 10.1016/0732-8893(90)90030-y. [DOI] [PubMed] [Google Scholar]
  5. Emmerson A. M. Cefuroxime axetil. J Antimicrob Chemother. 1988 Aug;22(2):101–104. doi: 10.1093/jac/22.2.101. [DOI] [PubMed] [Google Scholar]
  6. Finn A., Straughn A., Meyer M., Chubb J. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos. 1987 Nov-Dec;8(6):519–526. doi: 10.1002/bdd.2510080604. [DOI] [PubMed] [Google Scholar]
  7. Harding S. M., Williams P. E., Ayrton J. Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother. 1984 Jan;25(1):78–82. doi: 10.1128/aac.25.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hebblethwaite E. M., Brown G. W., Cox D. M. A comparison of the efficacy and safety of cefuroxime axetil and augmentin in the treatment of upper respiratory tract infections. Drugs Exp Clin Res. 1987;13(2):91–94. [PubMed] [Google Scholar]
  9. Hendrickse W. A., Kusmiesz H., Shelton S., Nelson J. D. Five vs. ten days of therapy for acute otitis media. Pediatr Infect Dis J. 1988 Jan;7(1):14–23. doi: 10.1097/00006454-198801000-00005. [DOI] [PubMed] [Google Scholar]
  10. Hugonot R., Hugonot L., Pappo M., Chiche D. Traitement ambulatoire par le céfuroxime-axetil des bronchites infectieuses du sujet de soixante ans ou plus: étude comparative avec l'association d'amoxicilline et d'acide clavulanique. Pathol Biol (Paris) 1990 Jun;38(5 ):533–537. [PubMed] [Google Scholar]
  11. Jorgensen J. H., Doern G. V., Maher L. A., Howell A. W., Redding J. S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990 Nov;34(11):2075–2080. doi: 10.1128/aac.34.11.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Knapp C. C., Washington J. A., 2nd In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother. 1988 Jan;32(1):131–133. doi: 10.1128/aac.32.1.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Maesen F. P., Davies B. I., Baur C. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis. J Antimicrob Chemother. 1987 Mar;19(3):373–383. doi: 10.1093/jac/19.3.373. [DOI] [PubMed] [Google Scholar]
  14. McLinn S. E., Moskal M., Goldfarb J., Bodor F., Aronovitz G., Schwartz R., Self P., Ossi M. J. Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children. Antimicrob Agents Chemother. 1994 Feb;38(2):315–318. doi: 10.1128/aac.38.2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Murray P. R. Antimicrobial activity of seven oral antibiotics against selected community- and hospital-acquired pathogens. Clin Ther. 1991 Mar-Apr;13(2):224–231. [PubMed] [Google Scholar]
  16. Murray P. R., Jones R. N., Allen S. D., Erwin M. E., Fuchs P. C., Gerlach E. H. Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):191–203. doi: 10.1016/0732-8893(93)90110-s. [DOI] [PubMed] [Google Scholar]
  17. Pichichero M. E., Gooch W. M., Rodriguez W., Blumer J. L., Aronoff S. C., Jacobs R. F., Musser J. M. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med. 1994 Oct;148(10):1053–1060. doi: 10.1001/archpedi.1994.02170100051010. [DOI] [PubMed] [Google Scholar]
  18. Pichichero M., Aronovitz G. H., Gooch W. M., McLinn S. E., Maddern B., Johnson C., Darden P. M. Comparison of cefuroxime axetil, cefaclor, and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children. South Med J. 1990 Oct;83(10):1174–1177. doi: 10.1097/00007611-199010000-00013. [DOI] [PubMed] [Google Scholar]
  19. Portier H., Chavanet P., Gouyon J. B., Guetat F. Five day treatment of pharyngotonsillitis with cefpodoxime proxetil. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):79–85. doi: 10.1093/jac/26.suppl_e.79. [DOI] [PubMed] [Google Scholar]
  20. Portier H., Chavanet P., Waldner-Combernoux A., Kisterman J. P., Grey P. C., Ichou F., Safran C. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis. 1994;26(1):59–66. doi: 10.3109/00365549409008592. [DOI] [PubMed] [Google Scholar]
  21. Schleupner C. J., Anthony W. C., Tan J., File T. M., Lifland P., Craig W., Vogelman B. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med. 1988 Feb;148(2):343–348. [PubMed] [Google Scholar]
  22. Strömberg A., Schwan A., Cars O. Five versus ten days treatment of group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis. 1988;20(1):37–46. doi: 10.3109/00365548809117215. [DOI] [PubMed] [Google Scholar]
  23. Todd P. A., Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990 Feb;39(2):264–307. doi: 10.2165/00003495-199039020-00008. [DOI] [PubMed] [Google Scholar]
  24. Washington J. A., Jones R. N., Gerlach E. H., Murray P. R., Allen S. D., Knapp C. C. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother. 1993 Aug;37(8):1696–1700. doi: 10.1128/aac.37.8.1696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Williams P. E., Harding S. M. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother. 1984 Feb;13(2):191–196. doi: 10.1093/jac/13.2.191. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES